Literature DB >> 8106018

Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies.

R J Soiffer1, M J Robertson, C Murray, K Cochran, J Ritz.   

Abstract

Interleukin-12 (IL-12) is a heterodimeric 70-kD cytokine that can enhance the activity of cytotoxic effector cells. Although IL-12 shares some functional properties with interleukin-2 (IL-2), it appears to act via a distinct mechanism. In this report, we examined the effects of IL-12 on the cytolytic activity and proliferation of peripheral blood mononuclear cells (PBMC) obtained from patients with malignant disease. PBMC from two groups of patients were evaluated. The first group consisted of 12 individuals with metastatic solid tumors. PBMC from these patients demonstrated a marked defect in their ability to lyse natural killer (NK)-sensitive targets (K562) compared with normal volunteers. Overnight incubation with IL-12 (35 pmol/L) corrected this defect. The effect of 35 pmol/L of IL-12 on cytotoxicity was similar to that of 3 nmol/L of IL-2. In contrast, this concentration of IL-12 had little effect on cytolytic activity against an NK-resistant cell line (COLO 205). When IL-12 was added to PBMC obtained from cancer patients who were being treated with low-dose IL-2 in vivo, a dramatic increase in cytolytic activity against both NK-sensitive and -resistant tumor targets was observed. Unlike IL-2, IL-12 failed to stimulate proliferation of resting PBMC from cancer patients significantly. The second group of patients we studied comprised 13 patients who had recently undergone allogeneic bone marrow transplantation (BMT) for hematologic malignancy. In resting PBMC from these transplant recipients, IL-12 was capable of enhancing cytotoxicity against both NK-sensitive and -resistant tumor targets. Our findings indicate that IL-12 can restore defective NK activity of PBMC from patients with metastatic cancer, as well as enhance cytolytic function of PBMC from patients after allogeneic BMT. The clinical use of IL-12 as an immunomodulator in patients with malignancy merits further consideration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106018

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Neuroimmune mechanisms in health and disease: 2. Disease.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

2.  Enhancement of the TCRζ expression, polyclonal expansion, and activation of t cells from patients with acute myeloid leukemia after IL-2, IL-7, and IL-12 induction.

Authors:  Li Shi; Shaohua Chen; Xianfeng Zha; Yan Xu; Ling Xu; Lijian Yang; Yuhong Lu; Kanger Zhu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2015-03-10       Impact factor: 3.311

3.  Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.

Authors:  M Caruso; K Pham-Nguyen; Y L Kwong; B Xu; K I Kosai; M Finegold; S L Woo; S H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12.

Authors:  Q H Nguyen; R L Roberts; B J Ank; S J Lin; C K Lau; E R Stiehm
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

Review 5.  The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1996-09       Impact factor: 6.968

6.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

7.  Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.

Authors:  Richard F Little; Karen Aleman; Pallavi Kumar; Kathleen M Wyvill; James M Pluda; Elizabeth Read-Connole; Victoria Wang; Stefania Pittaluga; Andrew T Catanzaro; Seth M Steinberg; Robert Yarchoan
Journal:  Blood       Date:  2007-09-10       Impact factor: 22.113

Review 8.  Interleukin 12: a new clinical player in cytokine therapy.

Authors:  R E Banks; P M Patel; P J Selby
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

9.  Human alveolar macrophages augment natural killer cell stimulatory factor (interleukin-12)-inducible killer activity from autologous blood lymphocytes.

Authors:  T Haku; S Sone; R Nabioullin; T Ogura
Journal:  Jpn J Cancer Res       Date:  1995-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.